Show simple item record

dc.contributor.authorHicks, RJ
dc.date.available2014-05-22T07:51:53Z
dc.date.issued2012-09-28
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000321002000003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4d813f4571fa7d6246bdc0dfeca3a1c
dc.identifier.citationHicks, R. J. (2012). Should positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer?. CANCER IMAGING, 12 (2), pp.315-323. https://doi.org/10.1102/1470-7330.2012.9005.
dc.identifier.issn1470-7330
dc.identifier.urihttp://hdl.handle.net/11343/33051
dc.descriptionC1 - Journal Articles Refereed
dc.description.abstractCancer is a major cause of illness and death in Western society and is associated with a heavy concomitant economic burden. Although use of imaging comprises only a small proportion of the fiscal impact of cancer, its use has been increasing over recent decades, causing concern amongst funders of health care and efforts to constrain the use of new imaging tests with a relatively high unit cost. In clinical practice, positron emission tomography/computed tomography (PET/CT) is generally performed when less expensive tests have left some uncertainty regarding appropriate management. In this setting, its utility relates to provision of incremental diagnostic information. However, given that superior diagnostic information can positively affect patient management, wherein the majority of costs reside, it may be both more efficient and cost effective to go directly to the most accurate investigation in certain situations. For PET/CT, the ability to provide more accurate assessment of metastatic status than is available from conventional diagnostic paradigms provides a rationale for its independent rather than incremental use in patients presenting with either a high likelihood of malignancy or proven malignancy of a locally advanced nature and an accordingly high risk of metastatic disease. A randomized trial design is described that could be used to test this hypothesis.
dc.formatapplication/pdf
dc.languageEnglish
dc.publisherBMC
dc.subjectCancer Diagnosis; Cancer and Related Disorders
dc.titleShould positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer?
dc.typeJournal Article
dc.identifier.doi10.1102/1470-7330.2012.9005
melbourne.peerreviewPeer Reviewed
melbourne.affiliationThe University of Melbourne
melbourne.affiliation.departmentThe Sir Peter Maccallum Department Of Oncology
melbourne.source.titleCANCER IMAGING
melbourne.source.volume12
melbourne.source.issue2
melbourne.source.pages315-323
melbourne.publicationid195802
melbourne.elementsid388609
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460557
melbourne.contributor.authorHicks, Rodney
dc.identifier.eissn1740-5025
melbourne.fieldofresearch321102 Cancer diagnosis
melbourne.seocode200199 Clinical health not elsewhere classified
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record